The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 study
| Autor: | Ramchandren, Radhakrishnan, Johnson, Peter, Ghosh, Nilanjan, Ruan, Jia, Ardeshna, Kirit M., Johnson, Roderick, Verhoef, Gregor, Cunningham, David, de Vos, Sven, Kassam, Shireen, Fayad, Luis, Radford, John, Bailly, Sarah, Offner, Fritz, Morgan, David, Munoz, Javier, Ping, Jerry, Szafer-Glusman, Edith, Eckert, Karl, Neuenburg, Jutta K., Goy, Andre |
|---|---|
| Zdroj: | In eClinicalMedicine February 2023 56 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|